Hepatitis Conferences | Liver Conferences | USA | Europe | Asia Pacific | Middle East

Theme: Treatment and Management strategies to eradicate Hepatitis and Liver diseases

Hepatitis 2016

Scientific Program

Renowned Speakers

Anil Kaul
Oklahoma State University
USA

Andre Jean Remy
Perpignan Hospital
France

Maxwell M Chait
Columbia University
USA

Ligita Jancoriene
Vilnius University
Lithuania

Arnolfo Petruzziello
IRCCS Italia - Fondazione â€œG. Pascale
Italy

Vince Fragomeli
Nepean Hospital
Australia

Andrew Vaillant
Replicor Inc
Canada

Prapan Jutavijittum
Chiang Mai University
Thailand

Hepatitis 2016

The liver supports almost every organ in the body and is vital for survival. Because of its strategic location and multidimensional functions, the liver is also prone to many diseases. Hepatitis is a common condition of inflammation of the liver. The most usual cause of this is viral, and the most common of these infections are hepatitis A, B, C, D, and E. Infection with hepatitis B virus or hepatitis C virus is the main cause of liver cancer. Other disorders caused by excessive alcohol consumption are grouped under alcoholic liver diseases and these include alcoholic hepatitis, fatty liver, and cirrhosis. Liver damage can also be caused by drugs, particularly paracetomol and drugs used to treat cancer.

Track 1: Genetic and Metabolic Liver Diseases

There are many inherited metabolic and genetic disorders that may have a pathologic impact on the liver. Haemochromatosis, Gilbert syndrome and Wilson’s disease are genetic disorders caused by accumulation of iron, bilirubin and copper in the liver. Alpha1-antitrypsin (α1-AT) deficiency is a disorder in which the normal processing of a liver-produced protein is disturbed within the liver cell.

Related Hepatitis Conferences | Liver Conferences | ConferenceSeries Ltd: 2^nd International Conference on Hepatology, May 09-11, 2016 Chicago, USA; 6^th Global Gastroenterologists Meeting, August 11-12, 2016 Birmingham, UK; 7^th Gastroenterology and Gastroenterologists Annual Meeting, September 12-14, 2016 Atlanta, USA; 8^th International Conference on Clinical Gastroenterology & Hepatology September 29-October 1, 2016 Toronto, Canada; 3^rd World Congress on Hepatitis and Liver Diseases, October 10-12, 2016 Dubai, UAE; International Conference on Pancreatic Disorders and Treatment, October 17-19, 2016 Chicago, USA; European Gastroenterology Conference, October 24-25, 2016 Valencia, Spain; International Conference on Endoscopy, November 17-18, 2016 Atlanta, USA; International Conference on Digestive Diseases, December 08-09, 2016 Dubai, UAE; Digestive Disease Week, May 21-24, 2016 San Diego, USA; International Course on Gastroenterology Trujillo 2016, June 30, 2016 - July 2, 2016 Peru; Pan American Digestive Disease Week, September 10-13, 2016 Columbia; 24th Annual Meeting of the Croatian Society of Gastroenterology, September 15-18, 2016 Croatia; XXII Russian Gastroenterological Week, October 03-05, 2016, Moscow, Russia; XXV Peruvian Congress of Digestive Diseases, October 05-08, 2016 Lima, Peru; Asian Pacific Digestive Week, November 02-05, 2016 Kobe, Japan; Japan Digestive Disease Week, November 03-06, 2016 Kobe, Japan; Seoul International Digestive Disease Symposium, November 24-25, 2016 South Korea; 57th Annual Conference of Indian Society of Gastroenterology, December 15-18, 2016 New Delhi, India; American Association for the Study of Liver Diseases; American Hepato-Pancreato-Biliary Association; American Liver Foundation; European Association for the Study of the Liver; Asian Pacific Association for the Study of the Liver; International Association for the Study of the Liver; British Association for the Study of the Liver; Canadian Association for the Study of the Liver; Canadian Liver Foundation; Children's Liver Disease Foundation; Euroliver Foundation; Hepatitis B Foundation; Hepatitis Foundation International; International Liver Transplantation Society; International Hepato Pancreato Biliary Association

Track 2: Hepatitis Care and Cure

Treatment of Hepatitis is on the cutting edge of medicine. Hepatitis B virus infection (HBV) has been recognized as a major health problem worldwide and Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Viral hepatitis treatment depends on how active the virus is in your body. Viral hepatitis is the most common cause of hepatitis worldwide. Other causes of non-viral hepatitis include alcoholic hepatitis and autoimmune hepatitis.

Related Hepatitis Conferences | Liver Conferences | ConferenceSeries Ltd: 2^nd International Conference on Hepatology, May 09-11, 2016 Chicago, USA; 6th Global Gastroenterologists Meeting, August 11-12, 2016 Birmingham, UK; 7^th Gastroenterology and Gastroenterologists Annual Meeting, September 12-14, 2016 Atlanta, USA; 8^th International Conference on Clinical Gastroenterology & Hepatology September 29-October 1, 2016 Toronto, Canada; 3^rd World Congress on Hepatitis and Liver Diseases, October 10-12, 2016 Dubai, UAE; International Conference on Pancreatic Disorders and Treatment, October 17-19, 2016 Chicago, USA; European Gastroenterology Conference, October 24-25, 2016 Valencia, Spain; International Conference on Endoscopy, November 17-18, 2016 Atlanta, USA; International Conference on Digestive Diseases, December 08-09, 2016 Dubai, UAE; Digestive Disease Week, May 21-24, 2016 San Diego, USA; International Course on Gastroenterology Trujillo 2016, June 30, 2016 - July 2, 2016 Peru; Pan American Digestive Disease Week, September 10-13, 2016 Columbia; 24th Annual Meeting of the Croatian Society of Gastroenterology, September 15-18, 2016 Croatia; XXII Russian Gastroenterological Week, October 03-05, 2016, Moscow, Russia; XXV Peruvian Congress of Digestive Diseases, October 05-08, 2016 Lima, Peru; Asian Pacific Digestive Week, November 02-05, 2016 Kobe, Japan; Japan Digestive Disease Week, November 03-06, 2016 Kobe, Japan; Seoul International Digestive Disease Symposium, November 24-25, 2016 South Korea; 57th Annual Conference of Indian Society of Gastroenterology, December 15-18, 2016 New Delhi, India; American Association for the Study of Liver Diseases; American Hepato-Pancreato-Biliary Association; American Liver Foundation; European Association for the Study of the Liver; Asian Pacific Association for the Study of the Liver; International Association for the Study of the Liver; British Association for the Study of the Liver; Canadian Association for the Study of the Liver; Canadian Liver Foundation; Children's Liver Disease Foundation; Euroliver Foundation; Hepatitis B Foundation; Hepatitis Foundation International; International Liver Transplantation Society; International Hepato Pancreato Biliary Association

Track 3: Hepatitis B

Hepatitis B is a liver infection caused by the Hepatitis B virus (HBV). HBV is transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids. HBV can survive outside the body at least 7 days and still be capable of causing infection. The best way to prevent hepatitis B is by getting the hepatitis B vaccine. The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which lead to liver injury and potentially cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.

Track 4: Hepatitis C

Hepatitis C is a devastating viral disease that generally progresses slowly, meaning patients often remain asymptomatic and unaware they are infected until very serious and often expensive complications emerge as a result of damage to the liver. It is estimated that about half of those infected are not aware that they carry the virus. The recent remarkable advances in treating hepatitis C built on incremental improvements achieved over the previous two decades to transform hepatitis C from a chronic, fatal disease, to an infection that with new and forthcoming treatments, can be potentially cured.

Track 5: Hepatitis Vaccination

The best way to prevent hepatitis is by getting the hepatitis vaccines. Vaccination is safe and effective and it is recommended for all. Efforts to develop a hepatitis C vaccine started more than 20 years ago, when the hepatitis C virus was identified. The hepatitis C virus is more variable than are the viruses that cause hepatitis A and hepatitis B. Hepatitis C virus occurs in at least six genetically distinct forms with 50 subtypes. A global vaccine would have to protect against all these variants of the virus.

Track 6: Liver Diseases Diagnostics

Screening for Liver diseases has been advocated with the intention of intervening to halt its progression. Abnormal liver tests are those that measure synthesis of proteins made by the liver (albumin, clotting factors) or the liver's capacity to metabolize drugs. The impact of diagnosis of hepatitis C virus on quality of life is worse in patients aware of their viral status compared with individuals unaware of their viral status.

Track 7: Liver Diseases

Liver diseases are caused by metabolic, genetic drug induced and due to autoimmune diseases. Hepatic coma also known as Hepatic encephalopathy is a metabolic abnormality caused by accumulation of toxic substances in the bloodstream that are normally removed by the liver. Haemochromatosis is a genetic disorder caused by accumulation of iron in the liver. Non-alcoholic fatty liver disease is a drug induced liver disease caused by accumulation of extra fat in liver cells that is not caused by alcohol, whereas Alcoholic liver disease is due to overconsumption of alcohol. Primary biliary cirrhosis is an autoimmune disease of the liver in which the bile ducts in liver are slowly destroyed.

Track 8: Liver Cancer

Hepatocellular carcinoma is the most common form of liver cancer in adults. It begins in the hepatocytes, the main type of liver cell. The production of cancer cells in the Liver is called hepato-carcinogenesis. Research is going on to develop drugs that builds liver cancer immunity and also identifying and understanding cancer stem cells and their properties to develop effective anti-cancer therapies.

Track 9: Pregnancy and Liver Diseases

Several disorders contribute to liver disease in pregnancy such as acute fatty liver of pregnancy (AFLP) and intrahepatic cholestasis of pregnancy (IHCP), hyperemesis gravidarum and hemolysis and elevated liver enzymes and low platelets (HELLP) syndrome. Liver disease such as acute viral hepatitis can occur in pregnancy and pregnancy may occur in a patient with underlying chronic liver disease including patients with cirrhosis and portal hypertension, and patients who have undergone liver transplantation.

Track 10: Non-Viral Hepatitis

Non-viral hepatitis is an inflammation of the liver caused by toxins, drugs, or other harmful chemicals that destroy cells in the liver (Hepatocytes). Acute hepatitis damages hepatocytes, make up 70-85% of the total mass of the liver. The disease is a growing problem due to the increasing number of dietary supplements with liver side effects. If hepatitis leads to liver failure, a liver transplant is the only treatment option that can improve survival

Track 11: Drug Discovery for Treatment of Hepatitis

In recent years, tremendous research advances are transforming treatment of Hepatitis. More than 90% of patients with the most common form of the disease can expect to be cured in as little as 8 weeks with newly approved antiviral therapies. More new medicines are on the way. Most of this progress has occurred in just the last three years with newer and more effective therapies transforming the trajectory of the disease for many patients. The scientific advances made in recent years by biopharmaceutical researchers as they combat the hepatitis C virus have already begun to have a tangible impact on thousands of patients.

Track 12: Clinical Liver Transplantation

Liver transplantation is the only treatment possible option for end-stage liver disease and acute liver failure. Research is going on development of artificial liver support, a technology based on artificial materials for partial replacement of liver function. Liver surgery comprises various operations of the liver for different disorders. The most common operation performed on the liver is a resection (removal of a portion of the liver).

ConferenceSeries Ltd will be honored to invite you to the 3^rd World Congress on Hepatitis and Liver diseases (Hepatitis 2016) to be held in beautiful city, Dubai, UAE during October 10-12, 2016. The conference highlights the theme “Treatment and Management strategies to eradicate Hepatitis and Liver diseases”.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and Conference Series, LLC. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

PeerPoint Medical Education Institute designates the live format for this educational activity for AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hepatitis 2016 will serve as a catalyst for the advancement of research in the field of Hepatitis and Liver diseases by connecting scientists within and across the globe, creating a environment conducive to information exchange, generation of ideas and acceleration of applications that benefit society. The event offers a best platform with its well organized scientific program to the audience which includes symposiums, workshops, keynote lectures, plenary talks, panel discussions and poster sessions on latest research and technological developments in the arena as well as therapeutic aspects. The conference invites Hepatologists, Gastroenterologists, Internists, Physicians, Microbiologists, Virologists, Pathologists, Oncologists, Surgeons, Toxicologists, Researchers, Students, Business delegates and Young researchers across the globe.

ConferenceSeries Ltd organizes 300+ International Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific Societies and publishes 400+ Open Access Journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Conference Opportunities

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4-5 member team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor booths
Sponsorships opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with clients

Pregnancy and Liver Diseases

Hepatitis is an inflammatory disorder of the liver, caused by viruses, drugs, and toxins. Viral hepatitis is one of the major global health care problems and kills around 1.5 million people worldwide every year. The prevalence of viral hepatitis varies from region to region, but is generally higher in Middle Eastern countries. The three major viruses that affect the liver, hepatitis A, B, and C (HAV, HBV, HCV). HAV is the most common cause of acute hepatitis in children in the Middle East. 10,000,000 new cases of Hepatitis A reported globally every year. The prevalence of HAV in Iran is very high. The seroprevalence of HAV was 85% in the capital Tehran, 96% in Hormozgan in southern Iran, and 99% in Golestan in the north of the country. In most areas of Iran, more than 90% of people aged 33 years or older are seropositive for anti-HAV antibody. The rate in the Middle East varies from 0.6% in Iraq to more than 8% in Sudan. The rate is 5.1% in Yemen, 3.6% in Algeria, and 3.5% in Kuwait and the occupied Palestinian territory.

More than 2 000 million people alive today have been infected with HBV at some time in their lives. Of these, about 350 million remain infected chronically and become carriers of the virus. Three quarters of the world’s population live in areas where there are high levels of infection. Every year there are over 4 million acute clinical cases of HBV, and about 25% of carriers, 1 million people a year, die from chronic active hepatitis, cirrhosis or primary liver cancer. High endemicity areas include sub-Saharan Africa, the Middle East, the central Asian Republics, and some countries in eastern Europe. In these areas, about 70 to 90% of the population becomes HBV-infected before the age of 40, and 8 to 20% of people are HBV carriers. In countries such as China, Senegal, and Thailand, infection rates are very high in infants, and continue through early childhood. At that stage the prevalence of HBsAg in serum may exceed 25%. HBV is well studied in Saudi Arabia where the prevalence in the general population is 4.25%. The genotype of the virus D predominates in the Middle East.

The highest prevalence (17.5%) of HCV in the world was reported in Egypt. The pooled prevalence of HCV in haemodialysis patients is 16% in Iran, 56% in Saudi Arabia, 52% in Syria, and 34% in Sudan. Patients infected with HBV and HCV have an increased risk of developing various liver diseases, including cirrhosis and hepatocellular carcinoma: 15–40% of patients infected with HBV are at risk of developing cirrhosis and hepatocellular carcinoma if left untreated. Roughly 1.5 million people in Iran are living with HBV and are at risk of developing cirrhosis and hepatocellular carcinoma. The high prevalence of HBV and HCV infections in some countries in the Middle East is alarming and is a challenge for health-care policy makers. Raising public awareness of viral hepatitis risk factors is an important step. Hepatitis screening in selected risk groups need to be implemented to reduce the future burden of viral infection.

Scope:

Hepatitis 2016 Conference is to bring top experts together and delegates for an in-depth discussion on Hepatitis and Liver diseases. To create awareness for both rural and urban population about liver disease it should be diagnosed at early stages. The importance of this conference is to update, clinically relevant audience regarding the evidence supporting current clinical practices in hepatocellular carcinoma and hepatitis medicine. The information presented is intended to enhance clinical competence in the diagnosis and treatment of hepatitis and liver disease. Hepatitis 2016 describes the health risks and effects associated with the Human life. This Conference will address scientific research to take new steps in therapeutics & techniques involved. The conference we are conducting on liver disease is to get awareness in the people. It will explain how to protect liver from hepatitis and other viral disease.

Hepatitis 2016 conference aims at gathering the audience from all the major parts of the world with a goal to enhance the scientific knowledge by exploring the latest advancements in the related conference field area. The conference will include explicit keynote and plenary sessions delivered by the distinguished researchers, scientists and honorary lecturers working in the field of hepatology. Hepatitis 2016 will encourage the participation of the eminent professors, researchers and students in all areas of hepatology and will provide an international forum for the dissemination of original research results, new ideas and practical development experiences concentrating on the scientific development.

Medical Universities in UAE:

Gulf Medical University
Dubai Medical College
RAK Medical & Health Sciences University
United Arab Emirates University
Dubai Medical College for Girls
University of Sharjah
King Saud University
University of Dammam
King Faisal University
Al Jouf University
Taibah University
Al-Majmaah University
Tabuk University
Taif University
King Khalid University
King AbdulazizUniversity
Batterjee Medical College for Science & Technology
Salman Bin Abdlaziz University

Pharmaceutical Companies in Dubai:

MPC Healthcare
Alain Pharmacy New
Alain Pharmacy Euro Health
Al Hayat Pharmaceuticals
Emirates Biotech Pharmaceutical Factory
AstraZeneca - Gulf
Lunatus
Pfizer UAE
Merck UAE
Gulf Pharmaceutical Industry-Julphar (JULPHAR)
Hikma Pharmaceuticals PLC
Elis Pharmaceuticals Limited
Sanofi Aventis UAE
Ranbaxy Laboratories Limited
GlaxoSmithKline
Saga Pharmaceuticals
Baxter A.G
Johnson & Johnson Middle East
Novo Nordisk Pharma Gulf
Smart Health and Nutrition Ltd.
Valeant Pharmaceuticals MEA FZ LLC
Amgen
Alliance Global
Genpharm
BioPharma
Gulf Inject
Global Pharma
NeoPharma
Medpharma

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 10-30, -0001
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2	Day 3
Poster Opportunity Closed	Click Here to View

Media Partners

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

Testimonials

Thank you for all your effort over the past months to make the conference successful. Thank you again also for giving us the opportunity to present our work.
Mamdooh Ghoneum, Charles Drew University, USA

I greatly appreciate your arrangement for such a wonderful conference. It was very successful
Sen-Yung Hsieh, Chang Gung Memorial Hospital, Taiwan

It was a pleasure to attend the conference. The conference was very good from my point of view covering all aspects of Hepatitis that are important for understanding, treatment and control of the disease. There were some very interesting discussions and I think everybody profited from the conference
Francisco Coutinho, Sao Paulo University, Brazil

Thank you for the opportunity of being part of OMICS Hepatitis conference
Mayson Aburaya, Rappaport Faculty of Medicine, Israel

I really enjoyed my stay at Orlando, I would like to thank conference organizers for a wonderful arrangement at venue
Garima Mittal, SRHU, India

The meeting in Florida was good, the scientific contents and the discussions were good
Hosny Salama, Cairo university, Egypt

The discussions during the conference were good.
Mark A Feitelson, Temple University, USA

2^nd International Congress on Viral Hepatitis October 10-30, -0001 Dubai, UAE

Recommended Global Gastroenterology Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links